Design, Synthesis, and Biological Evaluation of Selective PAK4 Degrader for the Treatment of Lung Tumor Metastasis
Related Experiment Video
Updated: Jun 17, 2026
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
Published on: March 12, 2018
Hanxun Wang1,2, Peilu Song1,3, Yujie Wang1
1Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.
Abstract:
PAK4, the most studied member of group II PAK, plays crucial roles in multiple cancer cell signaling pathways. To date , only PAK4 inhibitor KPT9274 is under clinical development with no detailed binding mechanism. The PROTAC technology offers a new chance to study PAK4 by selective protein degradation. Here, we report the development of CPS-021, a selective PAK4 degrader derived from our previously reported compound CPL-042 conjugated to pomalidomide. CPS-021 induced selective degradation of PAK4 with DC50 = 50 nM and exhibited significant antimigratory and invasive activity. The A549-luc lung metastasis in vivo model demonstrated that CPS-021 effectively inhibited the invasion and metastasis of tumor cells in nude mice. Our findings provide evidence that the selective PAK4 degrader exhibits significant pharmacological effects in suppressing cancer cell migration and invasion. These results support the further development of CPS-021 as a valuable tool compound for conducting in-depth biological investigations of group II PAKs.
Insights
A novel PAK4 degrader, CPS-021, effectively suppresses cancer cell migration and invasion. This PROTAC compound shows significant anti-metastatic activity in vivo, supporting its potential for cancer research.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- PAK4 is a key protein in cancer cell signaling pathways.
- Current PAK4 inhibitors lack detailed binding mechanisms.
- PROTAC technology enables targeted protein degradation.
Purpose of the Study:
- To develop a selective PAK4 degrader using PROTAC technology.
- To evaluate the anti-cancer effects of the novel degrader CPS-021.
- To investigate the pharmacological activity of CPS-021 in vitro and in vivo.
Main Methods:
- Development of CPS-021, a PROTAC molecule targeting PAK4.
- In vitro assessment of PAK4 degradation and anti-migratory/invasive activity.
- In vivo evaluation using an A549-luc lung metastasis model in nude mice.
Main Results:
- CPS-021 selectively degraded PAK4 with a DC50 of 50 nM.
- CPS-021 demonstrated significant antimigratory and invasive activity in vitro.
- CPS-021 effectively inhibited tumor cell invasion and metastasis in vivo.
Conclusions:
- Selective PAK4 degradation via CPS-021 exhibits potent anti-metastatic effects.
- CPS-021 is a promising tool compound for studying group II PAKs.
- Further development of CPS-021 is warranted for cancer research.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
